

(51) International Patent Classification:
C12Q 1/6809 (2018.01)(21) International Application Number:
PCT/SG2019/050517(22) International Filing Date:
18 October 2019 (18.10.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10201809232S 18 October 2018 (18.10.2018) SG

(71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).


(72) Inventors: SKANDERUP, Anders; c/o Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore 138672 (SG). GHOSHDASTIDER, Umesh; c/o Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore 138672 (SG).

(74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: METHOD FOR QUANTIFYING MOLECULAR ACTIVITY IN CANCER CELLS OF A HUMAN TUMOUR

FIG. 3



(57) **Abstract:** Disclosed herein is a method for predicting expression profiles of cancerous and non-cancerous cells respectively based on multiple sets of expression profiles, wherein each set of the multiple sets of expression profiles is obtained from tumour-derived samples comprising a mixture of cancerous and non-cancerous cells of one tumour type. The method comprises: a. determining tumour purity values for the tumour-derived samples, b. providing sets of expression profiles, wherein the sets of expression profiles comprise combined expression data for multiple or all molecules expressed by cancerous and non-cancerous cells comprised in the tumour-derived samples; and c. deconvoluting each combined expression data by extrapolating expression profiles to a tumour purity value at least substantially equal to 1 or 0; thereby predicting the expression profiles of the cancerous and non-cancerous cells respectively. In one embodiment, the tumour purity values are estimated from DNA, copy number, and mRNA expression data using a consensus approach.

[Continued on next page]

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*
